Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting
Open Access
- 4 March 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (1) , 13-22
Abstract
Purpose: To describe the outcomes of a pharmacist-led multi-center, collaborative patient education and proactive adverse event management program in a community-based oncology setting. Methods: Patients with EGFR mutation-positive ( EGFRm+) non-small cell lung cancer, newly prescribed with oral afatinib, and monitored as part of the Florida Cancer Specialists patient management program, were included in a retrospective, observational analysis. During follow-up, data were collected on adverse event frequency, and changes in afatinib dosing. Data analyses were descriptive and exploratory in nature. Results: The mean age of the 123 patients included in the analysis was 69 years, and 78% were female. At the time of the analysis, 3 patients had discontinued before receiving treatment, 89 patients had discontinued afatinib treatment, and 31 patients were continuing to receive afatinib treatment. The most common afatinib-related adverse events were diarrhea (85%), rash/skin reactions (58%), stomatitis/mucositis (19%), and paronychia (16%). Overall, 13% of patients discontinued due to afatinib-related adverse events. The median duration of treatment was 4 months in patients who discontinued due to adverse events, 6 months in those who discontinued for other reasons, and 18 months in those who were continuing to receive therapy. Afatinib dose-reductions were more frequent in patients continuing treatment versus those who discontinued due to adverse events (77% vs. 42%, respectively). Conclusions: Findings suggest that adverse events in patients with EGFRm + non-small cell lung cancer receiving afatinib can be successfully managed in a community-based, real-world setting with the help of collaborative pharmacist-led patient education, adverse event monitoring, and continuous support.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 31 references indexed in Scilit:
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family BlockerThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinicJournal of Evaluation in Clinical Practice, 2011
- Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinicJournal of Oncology Pharmacy Practice, 2011
- Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical careSupportive Care in Cancer, 2010
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on ImatinibJournal of Clinical Oncology, 2010
- A systematic review of interventions to improve recall of medical advice in healthcare consultationsJournal of the Royal Society of Medicine, 2009
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- Effect of a Pharmacy Care Program on Medication Adherence and Persistence, Blood Pressure, and Low-Density Lipoprotein CholesterolJAMA, 2006
- Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes2000